OncoTargets and Therapy (Apr 2020)
Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial–Mesenchymal Transition in Pancreatic Cancer Cells
Abstract
Hongchun Li,1 Miao Chen,2 Zhuying Yang,3 Qinxian Wang,1 Jiesheng Wang,1 Dong Jin,1 Xiuyun Yang,1 Fuxing Chen,1 Xiumin Zhou,4 Kexue Luo1 1Department of Cadre Health, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, People’s Republic of China; 2Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, People’s Republic of China; 3Department of Gastroenterology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, People’s Republic of China; 4Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, People’s Republic of ChinaCorrespondence: Kexue LuoDepartment of Cadre Health, Tongde Hospital of Zhejiang Province, 234 Gucui Road, Hangzhou 310012, Zhejiang, People’s Republic of ChinaTel +86 571 89972437Email [email protected]: Pancreatic cancer (PC) is one of the leading causes of cancer, with the lowest 5-year survival rate of all cancer types. Given the fast metastasis of PC and its resistance to surgery, radiotherapy, chemotherapy, and combinations thereof, it is imperative to develop more effective anti-PC drugs. Phillygenin (PHI) has been reported to exert anti-cancer, anti-bacterial, and anti‐inflammatory properties. However, the mechanism of PHI in the development of PC is still unclear.Methods: The cytotoxicity of PHI in pancreatic cancer cells was evaluated by MTT assay, and clonogenic assay was used to test the anti-proliferation of PHI. The pro-apoptotic effect of PHI was detected by flow cytometry analysis. The changes of epithelial–mesenchymal transition (EMT) in pancreatic cancer cells treated with PHI were determined by Western blot. Transwell assay was used to test the migration and invasion of PC cells after treatment with PHI. Molecular docking was used to predict the potential binding site of candidate target with PHI.Results: PHI could inhibit the proliferation, migration, and EMT of PC cells (PANC-1 and SW1990) and induce its apoptosis. Analysis of the Cancer Genome Atlas database indicated that elevated MELK levels correlated with poor overall survival (OS) and disease-free survival (DFS) of PC patients. In addition, molecular modeling showed that PHI may potentially target the catalytic domain of maternal embryonic leucine zipper kinase (MELK). Overexpression of MELK muted the anti-PC effects of PHI.Conclusion: PHI holds promise as a potent candidate drug for the treatment of PC via targeted MELK.Keywords: pancreatic cancer, phillygenin, MELK, proliferation, EMT, apoptosis
